Acute Lichenoid Pityriasis (PLEVA) — Comprehensive Disease Characteristics Report

Target disease

Acute lichenoid pityriasis is most consistently used in the clinical literature as a synonym for pityriasis lichenoides et varioliformis acuta (PLEVA), the acute pole of the pityriasis lichenoides (PL) spectrum; some sources also refer to PLEVA as Mucha–Habermann disease, and the most severe ulceronecrotic systemic variant as febrile ulceronecrotic Mucha–Habermann disease (FUMHD). (jung2020systematicreviewof pages 1-2, ma2024diagnosticchallengesof pages 1-3, fatturi2024pityriasislichenoidesassessment pages 1-2)

Table: This table compacts the main disease-characteristics evidence for acute lichenoid pityriasis (PLEVA), including epidemiology, phenotype, diagnosis, triggers, treatment outcomes, and prognosis. It is useful as a quick-reference scaffold for a disease knowledge base entry with source-linked claims.

1. Disease information

Overview / definition (current understanding)

PLEVA is an uncommon inflammatory papulosquamous dermatosis characterized clinically by crops of erythematous papules/papulovesicles that may become necrotic/hemorrhagic and can heal with varioliform scarring, with recurrences over time. (ma2024diagnosticchallengesof pages 1-3, jung2020systematicreviewof pages 1-2, marinhernandez2023acutelichenoidand pages 1-2)

Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

Within the retrieved primary and review sources in this run, ICD-10/ICD-11, MeSH, OMIM, Orphanet, and MONDO identifiers were not explicitly provided, so they cannot be safely asserted from the evidence base assembled here. (ma2024diagnosticchallengesof pages 1-3, jung2020systematicreviewof pages 1-2)

Common synonyms / alternative names

• Pityriasis lichenoides et varioliformis acuta (PLEVA) (marinhernandez2023acutelichenoidand pages 1-2, jung2020systematicreviewof pages 1-2)
• Mucha–Habermann disease (jung2020systematicreviewof pages 1-2, ma2024diagnosticchallengesof pages 1-3)
• Febrile ulceronecrotic Mucha–Habermann disease (FUMHD) (severe variant) (ma2024diagnosticchallengesof pages 1-3, fatturi2024pityriasislichenoidesassessment pages 1-2)

Evidence provenance

Evidence is primarily derived from aggregated disease-level resources (systematic reviews and cohort/case series) and supplemented by individual case reports. (jung2020systematicreviewof pages 1-2, marinhernandez2023acutelichenoidand pages 1-2, fatturi2024pityriasislichenoidesassessment pages 1-2)

2. Etiology

Disease causal factors (mechanistic hypotheses)

Etiopathogenesis remains uncertain. Frequently cited hypotheses include: 1) T-cell dyscrasia / lymphoproliferative process (i.e., antigen-driven clonal/oligoclonal T-cell expansion in skin), and 2) immune-complex hypersensitivity reaction to infectious/drug antigens. (ma2024diagnosticchallengesof pages 1-3, boos2013pityriasislichenoidesand pages 1-2, fatturi2024pityriasislichenoidesassessment pages 1-2)

Risk factors / triggers (2023–2024 emphasis)

Evidence supports PLEVA/PL being triggered (not proven caused) by infections, drugs, or vaccines in some patients.

In a 2024 pediatric series (n=41), triggers were documented in 11/41 (26.8%) patients, including fever (3), COVID-19 infection (2), and single cases of sun exposure, HIV, parotitis, tonsillitis, cold weather, and COVID-19 vaccination. (fatturi2024pityriasislichenoidesassessment pages 2-4)

A 2024 diagnostic-focused report lists reported infectious triggers (e.g., EBV, HIV, varicella-zoster virus, HSV-2, Toxoplasma gondii, group A streptococcus) and notes drug and vaccine triggers in the literature (including anti-TNF and vaccination). (ma2024diagnosticchallengesof pages 1-3)

A pediatric review summarizes that a preceding upper respiratory infection was reported in 33% and drug/vaccination exposure in 20% in one summarized series. (boos2013pityriasislichenoidesand pages 1-2)

Protective factors

No validated genetic or environmental protective factors were identified in the retrieved evidence. (jung2020systematicreviewof pages 1-2, fatturi2024pityriasislichenoidesassessment pages 1-2)

Gene–environment interactions

No specific gene–environment interaction findings were available in the retrieved full text, although one systematic review explicitly calls for future work on “understanding the interplay between genetic predisposition and environmental factors.” (everettUnknownyear…forpityriasisa pages 61-64)

3. Phenotypes

Core clinical phenotypes (with suggested HPO terms)

Key phenotypes include: * Crops of erythematous papules/papulovesicles, sometimes necrotic/hemorrhagic (suggested HPO: Papule [HP:0200031], Vesicle [HP:0100796], Skin ulcer [HP:0001053]) (ma2024diagnosticchallengesof pages 1-3, marinhernandez2023acutelichenoidand pages 1-2) * Crusting/necrosis and potential ulceration (HPO: Skin necrosis [HP:0001032], Crusting [HP:0030799]) (ma2024diagnosticchallengesof pages 1-3) * Pruritus (HPO: Pruritus [HP:0000989]) (rujimethapass2025pityriasislichenoidesin pages 5-6, boos2013pityriasislichenoidesand pages 1-2) * Varioliform scarring (HPO: Abnormal scar [HP:0100699]) (rujimethapass2025pityriasislichenoidesin pages 5-6, marinhernandez2023acutelichenoidand pages 1-2) * Post-inflammatory dyspigmentation (HPO: Hypopigmentation of the skin [HP:0001042]) (marinhernandez2023acutelichenoidand pages 1-2, rujimethapass2025pityriasislichenoidesin pages 5-6)

Age of onset

Onset often occurs in childhood/young adulthood; pediatric cohorts show onset peaks around preschool/early school ages. (jung2020systematicreviewof pages 1-2, rujimethapass2025pityriasislichenoidesin pages 5-6, fatturi2024pityriasislichenoidesassessment pages 1-2)

Severity and progression/course

PLEVA is typically acute/subacute and may recur in crops; a Thai pediatric cohort reported PLEVA duration range 1–20 months with mean ~4±2 months. (rujimethapass2025pityriasislichenoidesin pages 5-6)

Severe FUMHD can present with mucosal involvement, high fever, and systemic complications (e.g., sepsis, cardiomyopathy, pulmonary involvement). (ma2024diagnosticchallengesof pages 1-3)

Frequency among affected individuals

In pediatric PL cohorts, PLEVA frequency varies widely by setting and referral patterns; for example, in a 2024 pediatric Brazilian cohort PLEVA was 5/41 (12.2%). (fatturi2024pityriasislichenoidesassessment pages 1-2)

Quality of life impact

Formal HRQoL instruments were not reported in retrieved primary sources; however, a 2024 diagnostic report notes misdiagnosis can lead to substantial emotional/psychological stress (qualitative impact). (ma2024diagnosticchallengesof pages 1-3)

4. Genetic/molecular information

Causal genes / pathogenic variants

No causal genes or pathogenic germline variants were identified in the retrieved literature; PLEVA is generally treated as a complex inflammatory dermatosis rather than a monogenic disorder in these sources. (jung2020systematicreviewof pages 1-2, fatturi2024pityriasislichenoidesassessment pages 1-2)

Molecular findings (limited)

Immunophenotyping can show T-cell–predominant infiltrates. A 2023 pediatric case reported lesional IHC including CD3+, CD4+++, CD8+, CD7+++, and CD20−. (marinhernandez2023acutelichenoidand pages 1-2)

T-cell receptor clonality is variably detected and is not diagnostic of lymphoma by itself; a pediatric review summarized one study with monoclonal TCR rearrangement in 57% of PLEVA vs 8% of PLC, while another series found only 1/23 positive, emphasizing heterogeneity and uncertain clinical significance. (boos2013pityriasislichenoidesand pages 1-2)

5. Environmental information

Environmental contributors are mainly reported as triggering exposures (infections, drugs, vaccines) rather than chronic toxic or occupational exposures. (ma2024diagnosticchallengesof pages 1-3, fatturi2024pityriasislichenoidesassessment pages 2-4)

6. Mechanism / pathophysiology

Proposed causal chain (current consensus framing)

A common mechanistic framing is: antigenic stimulus (infectious agent, drug, vaccine) → cutaneous immune activation with T-cell–predominant interface/lichenoid dermatitis → keratinocyte injury/necrosis and vascular/inflammatory changes → papulonecrotic lesions with crusting → post-inflammatory dyspigmentation or varioliform scarring. (ma2024diagnosticchallengesof pages 1-3, marinhernandez2023acutelichenoidand pages 1-2, boos2013pityriasislichenoidesand pages 1-2)

Cellular processes and pathways (ontology suggestions)

Because the retrieved sources do not provide pathway-specific transcriptomic/proteomic findings, ontology terms are suggested at a high level based on clinicopathology: * GO biological processes: T cell activation, inflammatory response, keratinocyte apoptotic process, leukocyte migration (supported conceptually by interface/lichenoid pattern and T-cell infiltrates) (ma2024diagnosticchallengesof pages 1-3, marinhernandez2023acutelichenoidand pages 1-2) * Cell types (Cell Ontology): T cell (CL:0000084); plausible involvement of CD4-positive, alpha-beta T cell (CL:0000624) and CD8-positive, alpha-beta T cell (CL:0000625) consistent with reported IHC (marinhernandez2023acutelichenoidand pages 1-2)

Immune system involvement

PLEVA lesions show interface/lichenoid dermatitis with epidermotropism in some cases, and PLEVA may represent a benign clonal or oligoclonal T-cell–driven process in a subset. (ma2024diagnosticchallengesof pages 3-9, boos2013pityriasislichenoidesand pages 1-2)

7. Anatomical structures affected

Organ and tissue level

Primary involvement is the skin (UBERON: skin [UBERON:0002097]), with lesions commonly on trunk and extremities. (marinhernandez2023acutelichenoidand pages 1-2, ma2024diagnosticchallengesof pages 1-3)

Severe FUMHD can involve mucosa and systemic organs (cardiopulmonary involvement described). (ma2024diagnosticchallengesof pages 1-3)

Subcellular level

Not resolved in retrieved evidence.

8. Temporal development

• Onset pattern: acute/subacute crops of papules; individual lesions may resolve within weeks but new lesions recur (ma2024diagnosticchallengesof pages 1-3, marinhernandez2023acutelichenoidand pages 1-2)
• Course: variable, often self-limited but may persist months; pediatric cohort mean duration for PLEVA ~4 months (rujimethapass2025pityriasislichenoidesin pages 5-6)
• Severe course: FUMHD can be rapidly progressive with systemic complications (ma2024diagnosticchallengesof pages 1-3)

9. Inheritance and population

PLEVA is not presented as a Mendelian disorder in the retrieved sources; inheritance pattern and penetrance are not established. (jung2020systematicreviewof pages 1-2)

Epidemiology statistics (available)

• A systematic review cites incidence approximately 0.05% and notes slight male predominance and typical onset in late childhood/young adulthood. (jung2020systematicreviewof pages 1-2)
• A 2023 pediatric report estimated incidence as ~1/2000 inhabitants (noted as an estimate in that report). (marinhernandez2023acutelichenoidand pages 1-2)

Because these numbers come from different sources with different contexts, they should be treated as approximate. (jung2020systematicreviewof pages 1-2, marinhernandez2023acutelichenoidand pages 1-2)

10. Diagnostics

Clinical evaluation

PLEVA can mimic multiple papulovesicular/papulosquamous eruptions. Diagnostic work-up typically relies on clinical morphology and distribution plus biopsy confirmation. (ma2024diagnosticchallengesof pages 1-3, jung2020systematicreviewof pages 1-2)

Histopathology

Commonly described findings include lichenoid/interface dermatitis, parakeratosis, spongiosis, erythrocyte extravasation, epidermal necrosis, subepidermal blistering, and sometimes focal epidermotropism; one pediatric case highlighted lymphocytic vasculitis with focal epidermal necrosis. (ma2024diagnosticchallengesof pages 1-3, ma2024diagnosticchallengesof pages 3-9, marinhernandez2023acutelichenoidand pages 1-2)

Direct immunofluorescence may be negative for immune deposits at the dermal–epidermal junction (IgG/IgA/IgM/C3 negative in a reported case). (ma2024diagnosticchallengesof pages 1-3)

Differential diagnosis

A differential table extracted from a 2024 diagnostic paper highlights confusion with guttate psoriasis, varicella, pityriasis rosea, and secondary syphilis. (ma2024diagnosticchallengesof media c2c2a990)

Histopathology figures supporting interface dermatitis and focal epidermotropism are available from the same report. (ma2024diagnosticchallengesof media 72391849, ma2024diagnosticchallengesof media 01b2711c)

Omics/genetic testing

Routine genetic testing is not described for PLEVA in the retrieved sources. (jung2020systematicreviewof pages 1-2)

11. Outcome / prognosis

General prognosis

PLEVA is generally benign/self-limited but can be relapsing. (jung2020systematicreviewof pages 1-2, rujimethapass2025pityriasislichenoidesin pages 5-6)

Risk of progression to cutaneous T-cell lymphoma (CTCL)

Progression risk is debated; in a Thai pediatric cohort, 1/43 (2.3%) was later diagnosed as mycosis fungoides on repeat biopsy. (rujimethapass2025pityriasislichenoidesin pages 5-6)

Clinical concern for MF/CTCL is heightened when clinical morphology changes or the course is prolonged; a 2023 pediatric case illustrates diagnostic overlap when an initial biopsy was read as suggestive of mycosis fungoides but was later revised to PLEVA with lymphocytic vasculitis. (marinhernandez2023acutelichenoidand pages 1-2)

12. Treatment

Evidence quality (expert appraisal)

A 2020 systematic review (British Journal of Dermatology) notes: “The current literature consists almost entirely of uncontrolled studies, and none provides compelling data to support an evidence-based approach to PL treatment.” (May 2020). (jung2020systematicreviewof pages 1-2)

First-line and second-line approaches (real-world implementations)

Across reviews and recent summaries, narrow-band UVB (NB-UVB) phototherapy is commonly recommended as first-line, with oral erythromycin or low-dose methotrexate (± topical corticosteroids) used as second-line options. (ma2024diagnosticchallengesof pages 3-9, feschuk2023pityriasislichenoidesfollowing pages 1-3)

Quantitative treatment outcomes

Phototherapy (systematic review evidence): In a 2020 systematic review, complete response rates were reported as 75.0% (102/136) for NB-UVB and 69% (25/36) for PUVA, with relapse after phototherapy in 25.7% (66/257). (jung2020systematicreviewof pages 2-4)

Pediatric real-world outcomes (2024 series): In a 2024 pediatric cohort, overall remission was 71.9%; among antibiotic-treated patients remission was 56.6% (17/30); among phototherapy-treated patients remission was 80% (4/5). (fatturi2024pityriasislichenoidesassessment pages 1-2)

Pediatric phototherapy-focused evidence: A pediatric phototherapy literature review reported initial clearance rates of 89.6% for BB-UVB (with 23.1% recurrence), 73% for NB-UVB (with no recurrence), and 83% for PUVA (with 60% recurrence), with generally mild erythema as the main side effect. (maranda2016phototherapyforpityriasis pages 1-2)

Systemic therapy for severe disease (FUMHD)

FUMHD may require systemic immunosuppression; methotrexate is repeatedly cited as important in refractory PLEVA/FUMHD. (ma2024diagnosticchallengesof pages 3-9, rujimethapass2025pityriasislichenoidesin pages 5-6)

MAXO (Medical Action Ontology) suggestions

• Phototherapy (e.g., NB-UVB phototherapy) (jung2020systematicreviewof pages 2-4, maranda2016phototherapyforpityriasis pages 1-2)
• Systemic antibiotic therapy (macrolides/tetracyclines) (fatturi2024pityriasislichenoidesassessment pages 2-4, fatturi2024pityriasislichenoidesassessment pages 1-2)
• Topical corticosteroid therapy (supportive symptom control) (ma2024diagnosticchallengesof pages 3-9)
• Systemic immunosuppressive therapy (methotrexate; severe/refractory cases) (ma2024diagnosticchallengesof pages 3-9, rujimethapass2025pityriasislichenoidesin pages 5-6)

Clinical trials

A ClinicalTrials.gov search in this run returned no relevant interventional trials for PLEVA; retrieved NCT records were unrelated false positives. (clinical trial search output not relevant to PLEVA; no citeable PLEVA trial context IDs available)

13. Prevention

No evidence-based primary prevention strategies were identified in retrieved sources; because triggers are inconsistent and causality is unproven, prevention is limited to pragmatic measures (avoidance of suspected individual triggers when reproducibly associated) and close follow-up for severe/systemic features suggestive of FUMHD. (ma2024diagnosticchallengesof pages 1-3, ma2024diagnosticchallengesof pages 3-9)

14. Other species / natural disease

No evidence was found in the retrieved sources for naturally occurring PLEVA in other species or zoonotic considerations. (maranda2016phototherapyforpityriasis pages 1-2, ma2024diagnosticchallengesof pages 3-9)

15. Model organisms

No explicit model organism systems or animal models for PLEVA were described in the retrieved, PLEVA-focused texts in this run. (maranda2016phototherapyforpityriasis pages 1-2, ma2024diagnosticchallengesof pages 3-9)

Recent developments and latest research highlights (prioritize 2023–2024)

1) SARS-CoV-2 infection/vaccination temporal association literature (2023): A 2023 review of 14 cases reported that 9/14 (64.3%) followed vaccination and 4/14 (28.6%) followed infection; 12/14 (85.7%) had marked improvement or complete resolution at follow-up, and the authors state “Naranjo’s ADRPS suggests SARS-CoV-2 may be a ‘probable’ cause of PL,” while emphasizing uncertainty and possible coincidence. (Jan 2023; https://doi.org/10.1007/s13671-023-00380-1). (feschuk2023pityriasislichenoidesfollowing pages 3-4)

2) Pityriasis eruptions after COVID-19 vaccination (systematic review, 2023): A systematic review identified 94 patients with pityriasis/pityriasis-like eruptions after vaccination; PLEVA accounted for 7.4% of reported cases; biopsy was performed in 41/94. (Aug 2023; https://doi.org/10.4081/dr.2023.9742). (duzett2023pityriasisfollowingcovid19 pages 2-3)

3) Large pediatric series with quantified remission predictors (2024): A 2024 pediatric cohort reported documented triggers in 26.8% and remission rates by therapy (antibiotics vs phototherapy), and found remission odds were higher with onset after age 5 (OR 13.33). (Sep 2024; https://doi.org/10.1016/j.jped.2024.03.011). (fatturi2024pityriasislichenoidesassessment pages 2-4, fatturi2024pityriasislichenoidesassessment pages 1-2)

4) Diagnostic pitfalls and histopathology emphasis (2024): A 2024 diagnostic report underscores clinical overlap with guttate psoriasis/varicella/pityriasis rosea/secondary syphilis and provides histopathology examples (subepidermal blistering, interface dermatitis, focal epidermotropism) to support biopsy confirmation. (Nov 2024; https://doi.org/10.70672/bcfbzp08). (ma2024diagnosticchallengesof media c2c2a990, ma2024diagnosticchallengesof media 72391849, ma2024diagnosticchallengesof media 01b2711c)

References

1. (jung2020systematicreviewof pages 1-2): F. Jung, C. Sibbald, M. Bohdanowicz, J. Ingram, V. Piguet, V. Piguet, and V. Piguet. Systematic review of the efficacies and adverse effects of treatments for pityriasis lichenoides. British Journal of Dermatology, 183:1026-1032, May 2020. URL: https://doi.org/10.1111/bjd.18977, doi:10.1111/bjd.18977. This article has 30 citations and is from a highest quality peer-reviewed journal.

2. (ma2024diagnosticchallengesof pages 1-3): Abd Rahman MA, Jamani NA, Abdul Halim S, and Zainun N. Diagnostic challenges of pityriasis lichenoides et varioliformis acuta (pleva). Asian Journal of Medicine & Health Sciences, 7:279-287, Nov 2024. URL: https://doi.org/10.70672/bcfbzp08, doi:10.70672/bcfbzp08. This article has 0 citations.

3. (fatturi2024pityriasislichenoidesassessment pages 1-2): Aluhine L. Fatturi, Mariana A.P. Morgan, Jandrei R. Markus, Lucero Noguera-Morel, and Vânia O. Carvalho. Pityriasis lichenoides: assessment of 41 pediatric patients. Jornal de Pediatria, 100:527-532, Sep 2024. URL: https://doi.org/10.1016/j.jped.2024.03.011, doi:10.1016/j.jped.2024.03.011. This article has 9 citations and is from a peer-reviewed journal.

4. (rujimethapass2025pityriasislichenoidesin pages 5-6): MD¹ Nootchanard Rujimethapass, MD¹ Wanida Limpongsanurak, and MD¹ Srisupalak Singalavanija. Pityriasis lichenoides in thai children: a 10-years review of clinical and treatment outcome. Journal of the Medical Association of Thailand, 108:377-383, May 2025. URL: https://doi.org/10.35755/jmedassocthai.2025.5.377-383-02606, doi:10.35755/jmedassocthai.2025.5.377-383-02606. This article has 1 citations.

5. (boos2013pityriasislichenoidesand pages 1-2): Markus D. Boos, Sara S. Samimi, Alain H. Rook, Albert C. Yan, and Ellen J. Kim. Pityriasis lichenoides and cutaneous t cell lymphoma: an update on the diagnosis and management of the most common benign and malignant cutaneous lymphoproliferative diseases in children. Current Dermatology Reports, 2:203-211, Aug 2013. URL: https://doi.org/10.1007/s13671-013-0054-x, doi:10.1007/s13671-013-0054-x. This article has 6 citations.

6. (marinhernandez2023acutelichenoidand pages 1-2): Eduardo Marín-Hernández, Laura N. Escobar-García, Martha G. Contreras, Alfredo Valero-Gómez, and Georgina A. Siordia-Reyes. Acute lichenoid and varioliform pityriasis in a pediatric patient. Boletín Médico del Hospital Infantil de México, Jun 2023. URL: https://doi.org/10.24875/bmhim.22000043, doi:10.24875/bmhim.22000043. This article has 5 citations.

7. (ma2024diagnosticchallengesof pages 3-9): Abd Rahman MA, Jamani NA, Abdul Halim S, and Zainun N. Diagnostic challenges of pityriasis lichenoides et varioliformis acuta (pleva). Asian Journal of Medicine & Health Sciences, 7:279-287, Nov 2024. URL: https://doi.org/10.70672/bcfbzp08, doi:10.70672/bcfbzp08. This article has 0 citations.

8. (ma2024diagnosticchallengesof media c2c2a990): Abd Rahman MA, Jamani NA, Abdul Halim S, and Zainun N. Diagnostic challenges of pityriasis lichenoides et varioliformis acuta (pleva). Asian Journal of Medicine & Health Sciences, 7:279-287, Nov 2024. URL: https://doi.org/10.70672/bcfbzp08, doi:10.70672/bcfbzp08. This article has 0 citations.

9. (rujimethapass2025pityriasislichenoidesin pages 6-7): MD¹ Nootchanard Rujimethapass, MD¹ Wanida Limpongsanurak, and MD¹ Srisupalak Singalavanija. Pityriasis lichenoides in thai children: a 10-years review of clinical and treatment outcome. Journal of the Medical Association of Thailand, 108:377-383, May 2025. URL: https://doi.org/10.35755/jmedassocthai.2025.5.377-383-02606, doi:10.35755/jmedassocthai.2025.5.377-383-02606. This article has 1 citations.

10. (fatturi2024pityriasislichenoidesassessment pages 2-4): Aluhine L. Fatturi, Mariana A.P. Morgan, Jandrei R. Markus, Lucero Noguera-Morel, and Vânia O. Carvalho. Pityriasis lichenoides: assessment of 41 pediatric patients. Jornal de Pediatria, 100:527-532, Sep 2024. URL: https://doi.org/10.1016/j.jped.2024.03.011, doi:10.1016/j.jped.2024.03.011. This article has 9 citations and is from a peer-reviewed journal.

11. (everettUnknownyear…forpityriasisa pages 61-64): L Everett. … for pityriasis lichenoides chronica, pityriasis lichenoides et varioliformis acuta, and febrile ulceronecrotic mucha–habermann disease: a systematic review. Unknown journal, Unknown year.

12. (ma2024diagnosticchallengesof media 72391849): Abd Rahman MA, Jamani NA, Abdul Halim S, and Zainun N. Diagnostic challenges of pityriasis lichenoides et varioliformis acuta (pleva). Asian Journal of Medicine & Health Sciences, 7:279-287, Nov 2024. URL: https://doi.org/10.70672/bcfbzp08, doi:10.70672/bcfbzp08. This article has 0 citations.

13. (ma2024diagnosticchallengesof media 01b2711c): Abd Rahman MA, Jamani NA, Abdul Halim S, and Zainun N. Diagnostic challenges of pityriasis lichenoides et varioliformis acuta (pleva). Asian Journal of Medicine & Health Sciences, 7:279-287, Nov 2024. URL: https://doi.org/10.70672/bcfbzp08, doi:10.70672/bcfbzp08. This article has 0 citations.

14. (feschuk2023pityriasislichenoidesfollowing pages 1-3): Aileen M. Feschuk, Maxwell Green, Nadia Kashetsky, and Howard I. Maibach. Pityriasis lichenoides following sars-cov-2 infection/vaccination. Current Dermatology Reports, 12:27-32, Jan 2023. URL: https://doi.org/10.1007/s13671-023-00380-1, doi:10.1007/s13671-023-00380-1. This article has 7 citations.

15. (jung2020systematicreviewof pages 2-4): F. Jung, C. Sibbald, M. Bohdanowicz, J. Ingram, V. Piguet, V. Piguet, and V. Piguet. Systematic review of the efficacies and adverse effects of treatments for pityriasis lichenoides. British Journal of Dermatology, 183:1026-1032, May 2020. URL: https://doi.org/10.1111/bjd.18977, doi:10.1111/bjd.18977. This article has 30 citations and is from a highest quality peer-reviewed journal.

16. (maranda2016phototherapyforpityriasis pages 1-2): Eric Laurent Maranda, Megan Smith, Austin H. Nguyen, Vivek N. Patel, Lawrence A. Schachner, and Jimenez J. Joaquin. Phototherapy for pityriasis lichenoides in the pediatric population: a review of the published literature. American Journal of Clinical Dermatology, 17:583-591, Aug 2016. URL: https://doi.org/10.1007/s40257-016-0216-2, doi:10.1007/s40257-016-0216-2. This article has 27 citations and is from a peer-reviewed journal.

17. (feschuk2023pityriasislichenoidesfollowing pages 3-4): Aileen M. Feschuk, Maxwell Green, Nadia Kashetsky, and Howard I. Maibach. Pityriasis lichenoides following sars-cov-2 infection/vaccination. Current Dermatology Reports, 12:27-32, Jan 2023. URL: https://doi.org/10.1007/s13671-023-00380-1, doi:10.1007/s13671-023-00380-1. This article has 7 citations.

18. (duzett2023pityriasisfollowingcovid19 pages 2-3): Laura Duzett, Guadalupe Mercado, Vasiliki Tasouli-Drakou, Alicia Kane, and Alison Tam. Pityriasis following covid-19 vaccinations: a systematic review. Dermatology Reports, Aug 2023. URL: https://doi.org/10.4081/dr.2023.9742, doi:10.4081/dr.2023.9742. This article has 2 citations.

1. Disease Information

Overview

Pityriasis Lichenoides et Varioliformis Acuta (PLEVA) is a rare inflammatory skin disorder first described by Mucha in 1916 and Habermann in 1925 (PMID: 8864599). The disease is characterized by the abrupt onset of recurrent crops of erythematous papulovesicular lesions that undergo necrosis and crusting, predominantly affecting the trunk and proximal extremities. PLEVA represents the acute end of the pityriasis lichenoides (PL) spectrum, which also encompasses pityriasis lichenoides chronica (PLC) and the severe febrile ulceronecrotic Mucha-Habermann disease (FUMHD).

Key Identifiers

Synonyms and Alternative Names

• Pityriasis lichenoides et varioliformis acuta (PLEVA)
• Mucha-Habermann disease (MHD)
• Acute parapsoriasis
• Acute guttate parapsoriasis
• Parapsoriasis varioliformis
• Parapsoriasis acuta
• Pityriasis lichenoides acuta

The severe variant is known as: - Febrile ulceronecrotic Mucha-Habermann disease (FUMHD) - Degos disease (referring to the 1966 description by Degos of the febrile ulceronecrotic variant)

Information Sources

The information in this report is derived from aggregated disease-level resources including systematic reviews, retrospective cohort studies, case series, and individual case reports published in peer-reviewed literature. No large-scale electronic health record (EHR) studies or population registries specific to PLEVA exist.

2. Etiology

Disease Causal Factors

The etiology of PLEVA remains unknown. It is generally considered a T-cell-mediated inflammatory dermatosis rather than a true neoplastic process, although debate persists regarding its relationship to cutaneous T-cell lymphoproliferative disorders (PMID: 12203210). The leading etiologic hypothesis is that PLEVA represents a hypersensitivity reaction to an infectious agent, as suggested by Mucha-Habermann disease reviews: "The etiology of MH remains obscure, but it may be the result of a hypersensitivity reaction to an infectious agent" (PMID: 8864599).

Risk Factors

Infectious Triggers

Multiple infectious agents have been temporally associated with PLEVA onset: - Streptococcal infections: A case of PLC manifesting ten days after streptococcal pharyngitis has been documented (PMID: 39365630) - Varicella (chickenpox): FUMHD following suspected hemorrhagic chickenpox has been reported in a 20-month-old boy (PMID: 25627543) - SARS-CoV-2 infection/vaccination: A systematic review identified 14 cases of PL following COVID-19 infection or vaccination, with one case recurring after vaccination suggesting a possible association (PMID: 36688177) - Various COVID-19 vaccines (BNT162b2 Pfizer-BioNTech, Oxford-AstraZeneca, Sinopharm) have been temporally associated with PLEVA onset or flare-up (PMID: 35841285; PMID: 35617206; PMID: 34751995; PMID: 34617317; PMID: 35716105) - Other viruses: HIV, EBV, CMV, parvovirus B19, adenovirus, and VZV have been implicated in individual case reports - Toxoplasma gondii has been reported as a possible trigger

Demographic Risk Factors

• Age: PLEVA primarily affects children and young adults. Pediatric onset average is 6.5 years (PMID: 25816855)
• Sex: Male predominance in children (M:F ratio 1.7:1), but female predominance in adults (M:F ratio 0.6:1) (PMID: 41420620)

Genetic Risk Factors

• No causal genetic variants have been identified for PLEVA
• No GWAS studies have been conducted
• No susceptibility loci have been mapped
• PLEVA is not classified among the autoinflammatory keratinization diseases (AiKDs), unlike keratosis lichenoides chronica which involves NLRP1 mutations (PMID: 38103162)

Protective Factors

No specific genetic or environmental protective factors have been identified for PLEVA. This represents a significant knowledge gap.

Gene-Environment Interactions

No gene-environment interactions have been characterized for PLEVA, consistent with the absence of identified causal genes.

3. Phenotypes

Primary Cutaneous Phenotypes

1. Papulovesicular Eruption (Hallmark)

• HPO: HP:0200037 (Vesiculobullous skin lesion), HP:0200034 (Papule)
• Type: Physical manifestation / clinical sign
• Onset: Acute; mean age 6.5 years in children (PMID: 25816855)
• Severity: Mild to moderate; severe in FUMHD variant
• Progression: Episodic, with recurrent crops; self-limited
• Frequency: Present in virtually 100% of patients
• Description: Sudden onset of erythematous macules and papules that develop central vesiculation, necrosis, and hemorrhagic crusting. Individual lesions evolve through stages from erythematous papule to crusted/necrotic papule to healing with dyspigmentation
• QoL impact: Cosmetic concern; post-inflammatory pigmentary changes particularly distressing in darker-skinned individuals

2. Scaling and Crusting

• HPO: HP:0040189 (Scaling skin), HP:0001047 (Crusting erythematous dermatitis)
• Type: Physical manifestation
• Frequency: Nearly universal; mica-like crust on older lesions is characteristic
• Progression: Evolves from acute papule stage

3. Post-inflammatory Hypopigmentation

• HPO: HP:0007513 (Generalized hypopigmentation of skin)
• Type: Physical manifestation (sequela)
• Frequency: Very common, especially in children with darker skin phototypes. In one study, post-inflammatory dyspigmentation was seen in 60% of adults and 80% of children (PMID: 23488769)
• Details: A study of 21 PLC patients found hypopigmented lesions showed features of active (28.6%) or residual (52.4%) disease in addition to true PIH (19%) (PMID: 34751445)
• QoL impact: Significant cosmetic and psychosocial impact, particularly in skin of color populations (PMID: 36769891)

4. Pruritus

• HPO: HP:0000989 (Pruritus)
• Type: Symptom
• Frequency: Present in the majority of patients (PMID: 23488769); specifically mentioned in ~21% of pediatric lymphoproliferative cases (PMID: 38595050)
• Severity: Mild to moderate

5. Varioliform Scarring

• HPO: HP:0100699 (Scarring)
• Type: Physical manifestation (sequela)
• Frequency: Varioliform (smallpox-like) scars occur in >77% of resolved cases
• QoL impact: Permanent cosmetic change

FUMHD-Specific Phenotypes

6. Ulceronecrotic Skin Lesions

• HPO: HP:0200042 (Skin ulcer)
• Type: Physical manifestation
• Severity: Severe; rapidly coalescing necrotic papules forming large ulcers
• Frequency: Defining feature of FUMHD (100%)

7. High Fever

• HPO: HP:0001945 (Fever)
• Type: Systemic sign
• Frequency: Universal in FUMHD
• Severity: High fever, often sustained

8. Systemic Involvement

• HPO: HP:0025155 (Disseminated intravascular coagulation)
• Type: Laboratory abnormality / systemic complication
• Frequency: Common in FUMHD. Systemic manifestations include DIC, pulmonary, cardiac, gastrointestinal, and CNS involvement (PMID: 38959922)

4. Genetic/Molecular Information

Causal Genes

No causal genes have been identified for PLEVA. The disease is not listed in OMIM as a genetic disorder, and no Mendelian inheritance pattern has been established.

T-Cell Clonality

While not a traditional "genetic" finding, T-cell receptor gene rearrangement studies are central to understanding PLEVA's molecular biology:

• T-cell clonality has been demonstrated in a subset of PL cases: "Pityriasis lichenoides (PL) is a papulosquamous disorder often considered a form of reactive dermatosis... however, some patients with PL have developed large plaque parapsoriasis (LPP) and mycosis fungoides (MF), and lymphoid atypia and T-cell clonality have been reported in lesions of PL" (PMID: 12203210)
• Monoclonal T-cell receptor rearrangement was found in 77% of tested skin biopsies in pediatric lymphomatoid papulosis, a related condition (PMID: 38595050)
• Among PL-like MF cases, monoclonality was demonstrated in 15 of 20 tested cases (PMID: 31032790)

Phenotypic Aberrations and MF Overlap

A subset of PL cases shows loss of pan-T-cell markers: "a subset of PL cases, particularly those exhibiting a loss of pan-T-cell markers (CD2, CD5, CD7), or T-cell clonality, may have a closer association with MF" (PMID: 40953932). This phenotypic aberration is a potential molecular marker for progression risk.

Epigenetic Information

No epigenetic studies (DNA methylation, histone modifications) specific to PLEVA have been published.

Chromosomal Abnormalities

No chromosomal abnormalities have been associated with PLEVA.

5. Environmental Information

Environmental Factors

No specific environmental toxins, radiation exposures, or occupational factors have been linked to PLEVA.

Lifestyle Factors

No specific lifestyle factors (smoking, diet, exercise, alcohol) have been associated with PLEVA risk.

Infectious Agents

PLEVA is hypothesized to represent a hypersensitivity response to infectious agents. The following pathogens have been temporally associated with disease onset:

Notably, a systematic review found no cases of Chlamydophila pneumoniae respiratory infection associated with PLEVA (PMID: 32222707).

6. Mechanism / Pathophysiology

Immunopathogenic Model

The current mechanistic understanding of PLEVA centers on a CD8+ cytotoxic T-lymphocyte-mediated immune response directed at keratinocytes and dermal vasculature:

Trigger (infectious agent/antigen)
|
v
Activation of adaptive immune response
|
v
CD8+ cytotoxic T-cell expansion and skin homing
|
v
Interface dermatitis: CD8+ T-cells attack basal keratinocytes
|
|---> Keratinocyte apoptosis/necrosis --> Epidermal disruption
|
|---> Lymphocytic vasculitis --> Erythrocyte extravasation
|
+---> Inflammatory cascade --> Papulovesicular eruption
            |
            v
Resolution with post-inflammatory pigmentary changes

Immune System Involvement

The predominant T-cell infiltrate in PLEVA is dominated by CD8+ T-cells (PMID: 38973067). This distinguishes PLEVA from classic mycosis fungoides, which is typically CD4+ dominant.

Key immunological features: - CD8+ T-cell predominance: Immunophenotyping consistently shows CD8+ dominance in PLEVA lesional infiltrates - Polyclonal CD8+ T-cell response has been documented in FUMHD with elevated pro-inflammatory cytokines and fivefold upregulation of CD64 on granulocytes (PMID: 25627543) - Loss of pan-T-cell markers (CD2, CD5, CD7) in a subset of cases suggests potential for immune dysregulation or malignant transformation (PMID: 40953932)

GO terms: GO:0006955 (immune response), GO:0002456 (T cell mediated immunity), GO:0006968 (cellular defense response), GO:0042110 (T cell activation)

Cellular Processes

1. Apoptosis / Keratinocyte Necrosis (GO:0006915): Interface dermatitis with necrotic keratinocytes is a universal histopathological feature (100% of cases) (PMID: 31880634)
2. Vasculitis (GO:0006954, inflammation): Lymphocytic vasculitis without fibrinoid deposition is seen in all PLEVA cases (PMID: 17456915)
3. Exocytosis of lymphocytes into epidermis (epidermotropism) in 45.1% of cases (PMID: 17456915)

Cell Types Involved

Tissue Damage Mechanisms

Tissue damage in PLEVA occurs through: 1. Cytotoxic T-cell-mediated keratinocyte killing leading to interface dermatitis with vacuolar changes 2. Lymphocytic vasculitis leading to erythrocyte extravasation, vascular injury 3. Inflammatory mediator release leading to edema, local tissue destruction 4. In FUMHD: massive necrosis with potential for DIC, sepsis, and multi-organ failure

Molecular Profiling

No dedicated transcriptomic, proteomic, or metabolomic studies of PLEVA lesional tissue have been published. This is a significant knowledge gap.

7. Anatomical Structures Affected

Organ Level

• Primary organ: Skin (UBERON:0002097) — the sole organ directly affected in typical PLEVA
• Secondary organ involvement (FUMHD only): Lungs, heart, GI tract, CNS (PMID: 38959922)
• Body system: Integumentary system; immune system (secondary)

Tissue and Cell Level

• Epidermis (UBERON:0001003): Interface dermatitis, keratinocyte necrosis, vesiculation
• Dermis (UBERON:0002067): Perivascular lymphocytic infiltrate, erythrocyte extravasation
• Dermal vasculature (UBERON:0002049): Lymphocytic vasculitis
• Adnexal structures: Lymphocytic infiltration into adnexal epithelium in 97% of cases (PMID: 31880634)

Localization

• Lateralization: Bilateral, generally symmetric distribution

8. Temporal Development

Onset

• Typical age of onset: Childhood and young adulthood
• Pediatric: Mean 6.5 years (PMID: 25816855)
• Adult: Mean ~42 years in Asian populations (PMID: 23488769)
• Onset pattern: Acute — sudden appearance of crops of papulovesicular lesions
• FUMHD was first reported in children and occurs more frequently in children, though adult cases have higher mortality (PMID: 8864599)

Progression

• Disease course: Episodic / relapsing-remitting; self-limited in most cases
• Duration:
• Median time to resolution: 8 months in adults, 21 months in children (PMID: 23488769)
• Some patients experience prolonged courses lasting years
• Progression to CTCL: Rare; 3 of 58 (5.2%) PL patients developed MF after 3-11 years (PMID: 29210716)

Remission Patterns

• Spontaneous remission: Common; 85% of non-MF PL patients achieved lasting complete remissions (PMID: 29210716)
• Treatment-induced remission: Achievable with phototherapy, antibiotics, or immunosuppressive agents
• Recurrence: Variable; NB-UVB shows lowest recurrence rate (0%) vs. PUVA (60%) (PMID: 27502793)

9. Inheritance and Population

Epidemiology

A long-term cohort of 242 PL patients (107 adults, 135 children) demonstrated: "The results show a male-to-female ratio of 1.7:1 for pediatric patients and 0.6:1 for adults, with a higher incidence of male patients among children (p < 0.01)" (PMID: 41420620).

Inheritance

PLEVA does not follow Mendelian inheritance. No familial aggregation, genetic anticipation, or consanguinity effects have been documented. The disease is considered sporadic with possible multifactorial etiology involving immune dysregulation triggered by environmental factors.

Population Demographics

• Affected populations: All ethnic groups; no clear ethnic predisposition
• Geographic distribution: Worldwide; no endemic areas identified
• Skin of color considerations: Post-inflammatory hypopigmentation is particularly prominent and clinically significant in darker-skinned patients. PLC may present with extensive hypopigmentation and prominent facial involvement in Black patients (PMID: 20408509)
• Age distribution: Bimodal — peak in childhood (~5-10 years) and young adulthood

10. Diagnostics

Clinical Diagnosis

Diagnosis of PLEVA is based on clinical presentation confirmed by histopathological examination. The characteristic pattern of lesions in different stages of development — ranging from erythematous maculopapules to papules with a crusted and/or necrotic centre — is suggestive, but biopsy is typically required (PMID: 37847066).

Biopsy / Histopathology (Gold Standard)

Histopathological findings in PLEVA are highly characteristic. A study of 71 PL cases quantified the frequency of key features:

All inflammatory cells are small- to medium-sized lymphocytes with no eosinophils observed. A deep dermal lymphocytic infiltrate with a T-shaped periadnexal arrangement has been described as a potentially distinguishing feature (PMID: 31880634).

Immunohistochemistry

Essential for: - Confirming CD8+ T-cell predominance (CD3+, CD8+, CD4-) - Detecting loss of pan-T-cell markers (CD2, CD5, CD7) — suggestive of atypical PL with MF overlap - Excluding CD30+ lymphoproliferative disorders (lymphomatoid papulosis) - CD20 negativity (excludes B-cell processes)

Dermoscopy

Dermoscopic findings correlating with histopathology include: - Punctate or glomerular vessels - Erythematous globules surrounding a homogeneous orange or crusty central area - These findings may allow rapid non-invasive diagnosis (PMID: 37847066)

Molecular Studies

• T-cell receptor gene rearrangement: Demonstrates clonality in ~50% of PL cases; presence does not necessarily indicate malignancy
• Monoclonal rearrangement is a negative prognostic indicator in FUMHD, associated with worse outcomes (PMID: 36483219)

Differential Diagnosis

Genetic Testing

Not applicable — no causal genes identified. However, TCR gene rearrangement analysis is clinically useful for risk stratification.

11. Outcome / Prognosis

Standard PLEVA

• Prognosis: Generally excellent. In the largest long-term follow-up study (242 patients, median 9.9 years), "no progression to cutaneous T-cell lymphoma was established. PL encompasses a spectrum of papulosquamous disorders... the study results underscore the benign course of PL" (PMID: 41420620)
• Remission: 85% of patients achieved lasting complete remissions (PMID: 29210716)
• MF progression risk: 5.2% (3/58) over 3-11 years in one study (PMID: 29210716)
• Mortality: Near zero for standard PLEVA/PLC

FUMHD (Severe Variant)

The prognosis for FUMHD is significantly worse:

Source: Systematic review of 119 FUMHD cases (PMID: 34287852)

Mortality risk factors (from systematic review): - Sepsis (LR 24.97, P < 0.001) - Systemic involvement (LR 19.97, P < 0.001) - Adult age (LR 11.19, P = 0.001) - Mucosal involvement (LR 4.58, P = 0.032)

A mortality risk score has been proposed: Age/10 + 4 + 4 (systemic involvement) + 1 (mucosal involvement), with sensitivity 93% and specificity 77% (PMID: 34287852).

Additional prognostic factors: "Increased age, systemic involvement, and monoclonal T-cell receptor rearrangement were associated with worst prognosis" (PMID: 36483219).

Quality of Life

• Post-inflammatory hypopigmentation and scarring represent the primary long-term morbidity
• Hypopigmentation is especially prominent and psychosocially distressing in darker-skinned populations (PMID: 36769891)
• Prolonged disease courses (median 21 months in children) impact daily life

12. Treatment

First-Line Treatment

Oral Antibiotics (MAXO:0000747 - antimicrobial therapy)

• Erythromycin: Recommended first-line in children; clearance rates 66-83% (PMID: 31318465)
• Azithromycin: 250 mg daily for 3 weeks reported to achieve rapid complete resolution (PMID: 38025325)
• Mechanism likely anti-inflammatory rather than antimicrobial

Topical Corticosteroids (MAXO:0000571 - topical corticosteroid therapy)

• Most commonly trialed treatment modality
• Limited efficacy as monotherapy; most patients did not respond to topical corticosteroids alone (PMID: 23488769)

Second-Line Treatment

Phototherapy (MAXO:0000596 - phototherapy)

The most effective treatment modality overall: "Of these treatments, phototherapy led to complete remission in the highest proportion of patients" (PMID: 32112390).

NB-UVB is the preferred modality due to excellent clearance with no recurrence and a favorable side-effect profile, especially in children (PMID: 41483505; PMID: 40013426).

"Narrow-band UVB showed an efficacy similar to PUVA as such as the combination of UVA and UVB vs. PUVA. Oral erythromycin showed clearance rates ranging between 66% and 83%, whereas methotrexate up to 100% but in small and dated studies" (PMID: 31318465).

Third-Line / Refractory Disease

Methotrexate (MAXO:0001024 - immunosuppressive therapy)

• Clearance up to 100% in small, dated studies (PMID: 31318465)
• Used for recalcitrant PLEVA and FUMHD

FUMHD-Specific Treatment

Given the life-threatening nature of FUMHD, aggressive multimodal therapy is required:

Treatment Algorithm

Step 1: Oral antibiotics (erythromycin/azithromycin) +/- topical corticosteroids
    |
    |-- Response --> Continue; monitor
    |
    +-- No response (4-8 weeks)
    |
    v
Step 2: NB-UVB phototherapy (2-3x/week)
    |
    |-- Response --> Taper; monitor
    |
    +-- No response / contraindicated
    |
    v
Step 3: Methotrexate or other systemic immunosuppression
    |
    v
FUMHD: Immediate systemic steroids + MTX or cyclosporine +/- IVIG
Consider etoposide/dexamethasone if HLH develops

Treatment Limitations

No randomized controlled trials exist for any PLEVA treatment. All evidence is based on case reports, case series, and retrospective studies. This is the most significant gap in clinical management.

13. Prevention

Primary Prevention

No primary prevention strategies exist for PLEVA. The unknown etiology precludes targeted prevention. General immune health maintenance is the only broadly applicable recommendation.

Secondary Prevention (Early Detection)

• Prompt skin biopsy of suspicious papulovesicular eruptions for early diagnosis
• Awareness among pediatricians that dermatologic complaints account for up to 30% of visits and PLEVA may be misdiagnosed (PMID: 41633545)
• Dermoscopy may allow non-invasive early diagnosis, reducing need for biopsy in infants (PMID: 37847066)

Tertiary Prevention

• Long-term dermatological follow-up to detect possible MF progression
• Patients with atypical phenotype (loss of CD2, CD5, CD7) and T-cell clonality warrant closer monitoring (PMID: 29851705)
• Management of post-inflammatory hypopigmentation to minimize psychosocial impact

Screening

No population-level screening programs exist or are warranted given the rarity and generally benign nature of the disease.

14. Other Species / Natural Disease

Natural Disease in Animals

No naturally occurring animal models of PLEVA have been identified. PL is considered a human-specific inflammatory dermatosis. No equivalent condition has been reported in companion animals, livestock, or wildlife in the OMIA database or veterinary literature.

Comparative Biology

• The CD8+ T-cell-mediated cytotoxic mechanism in PLEVA shares features with graft-versus-host disease (GVHD) and other interface dermatitis conditions that have been studied in mice, but no direct comparative pathology studies exist for PLEVA specifically
• Lymphocytic vasculitis of dermal vessels is not unique to PLEVA and occurs in various immune-mediated conditions across species

Zoonotic Potential

Not applicable — PLEVA is a non-infectious inflammatory dermatosis.

15. Model Organisms

Available Models

No established animal models exist for PLEVA. This is a critical knowledge gap. The absence of models reflects: 1. Unknown etiology making it difficult to design recapitulation strategies 2. The likely multifactorial nature of the immune trigger 3. Difficulty replicating the specific CD8+ T-cell-mediated interface dermatitis pattern

Potential Model Approaches

While not yet developed, potential approaches could include: - Adoptive transfer models: Transfer of activated CD8+ T-cells specific for keratinocyte antigens into syngeneic mice - Transgenic models: Mice expressing specific TCR recognizing epidermal antigens under controlled activation - Humanized mouse models: Engraftment of human T-cells from PLEVA patients into immunodeficient mice - In vitro models: Co-culture of CD8+ T-cells with keratinocyte monolayers/organoids to study cytotoxic mechanisms

Related Model Systems

The GVHD mouse model shares histopathological features with PLEVA (interface dermatitis, lymphocytic vasculitis, keratinocyte apoptosis) and has been used to study similar pathogenic mechanisms, though it is not specific to PLEVA.

Key Findings (Expanded)

Finding 1: CD8+ T-Cell-Mediated Pathogenesis

PLEVA is fundamentally a CD8+ cytotoxic T-lymphocyte-mediated inflammatory dermatosis. Immunophenotyping studies consistently demonstrate that the predominant T-cell infiltrate in PLEVA lesions is dominated by CD8+ cells (PMID: 38973067). T-cell receptor gene rearrangement analysis demonstrates monoclonality in a subset of cases, raising questions about the boundary between reactive inflammation and lymphoproliferation (PMID: 12203210). Importantly, a subset of cases showing loss of pan-T-cell markers (CD2, CD5, CD7) may have a closer association with mycosis fungoides, suggesting a spectrum rather than a clear demarcation (PMID: 40953932).

Finding 2: Age- and Sex-Dependent Demographics

The largest long-term PL cohort (242 patients) revealed a striking sex-specific age pattern: male predominance among children (M:F = 1.7:1, p < 0.01) contrasted with female predominance among adults (M:F = 0.6:1) (PMID: 41420620). The average age of onset in children is 6.5 years (PMID: 25816855). This reversal of sex predominance between age groups is unusual among dermatological conditions and may reflect sex-specific immune maturation differences.

Finding 3: FUMHD Mortality Stratification

The severe FUMHD variant carries dramatically different mortality across age groups: 2% in children vs. 20% in adults (overall 12%) (PMID: 34287852). Sepsis (LR 24.97), systemic involvement (LR 19.97), and adult age (LR 11.19) are statistically significant mortality predictors. A proposed risk score achieves 93% sensitivity and 77% specificity for predicting fatal outcomes, providing a clinically actionable tool for triage. Monoclonal T-cell receptor rearrangement was also associated with worse prognosis (PMID: 36483219).

Finding 4: Phototherapy Superiority

Among all treatment modalities, phototherapy achieves the highest complete remission rates. NB-UVB demonstrates 73% clearance with 0% recurrence — the best balance of efficacy and durability — while PUVA shows higher initial clearance (83%) but unacceptable recurrence (60%) (PMID: 27502793; PMID: 32112390). Oral erythromycin remains appropriate first-line therapy in children, with 66-83% clearance rates (PMID: 31318465). Phototherapy is considered safe and effective in the pediatric population with NB-UVB as the preferred modality (PMID: 41483505).

Finding 5: Hallmark Histopathological Features

The histopathological triad of PLEVA — interface dermatitis with necrotic keratinocytes (100%), perivascular lymphocytic infiltrate (99%), and erythrocyte extravasation (83%) — provides reliable diagnostic criteria (PMID: 31880634). Lymphocytic vasculitis without fibrinoid deposition is universally present in PLEVA (PMID: 17456915). The absence of eosinophils and the small-to-medium lymphocyte size help distinguish PLEVA from drug reactions and other inflammatory dermatoses.

Finding 6: Benign Natural History with Rare Lymphoma Risk

Long-term follow-up data are reassuring: in the largest cohort (242 patients, median 9.9 years), no progression to CTCL was established (PMID: 41420620). However, a separate study identified 5.2% (3/58) MF progression after 3-11 years of prolonged clinical course (PMID: 29210716). The discrepancy likely reflects patient selection and surveillance intensity. Cases with atypical phenotype and T-cell clonality warrant closer monitoring (PMID: 29851705).

Evidence Base

Landmark and Key Studies

Limitations and Knowledge Gaps

Major Knowledge Gaps

1. Unknown etiology: Despite decades of research, the specific trigger(s) for PLEVA remain unidentified. The infectious hypersensitivity hypothesis lacks definitive evidence.

2. No randomized controlled trials: All treatment evidence is Level 3-4 (case series, retrospective studies). No RCTs have been conducted for any PLEVA treatment modality.

3. No identified causal genes: PLEVA has no established genetic basis, precluding genetic testing, screening, or personalized medicine approaches.

4. No animal models: The absence of animal models severely limits mechanistic investigation and preclinical drug testing.

5. No omics profiling: No dedicated transcriptomic, proteomic, metabolomic, or epigenomic studies have been performed on PLEVA tissue.

6. Limited epidemiological data: Exact prevalence and incidence figures are unavailable due to the rarity of the condition and lack of disease registries.

7. Biomarker gap: No circulating biomarkers have been identified for diagnosis, prognosis, or treatment monitoring.

Study Limitations

• Most evidence derives from retrospective case series and reports with inherent selection bias
• Treatment response data lack standardized outcome measures
• Histopathological diagnostic criteria vary between centers
• The relationship between PL and MF/CTCL remains incompletely understood
• COVID-19 vaccine association data are based on temporal association only and cannot establish causality (PMID: 36688177)

Proposed Follow-up Experiments / Actions

High Priority

1. Multi-center prospective registry: Establish an international PL registry to capture standardized clinical, histopathological, immunophenotypic, and molecular data. This would address the epidemiological data gap and enable natural history studies.

2. Lesional transcriptomics/single-cell RNA sequencing: Perform scRNA-seq on PLEVA lesional skin biopsies vs. matched controls to:

3. Characterize the CD8+ T-cell populations (effector, memory, exhausted phenotypes)
4. Identify target antigens through TCR repertoire analysis

5. Discover pathway-level therapeutic targets

6. Randomized controlled trial: NB-UVB vs. oral erythromycin: Given that these are the two most commonly used treatments, a head-to-head RCT (targeting 100+ patients across multiple centers) would provide Level 1 evidence for treatment guidelines.

Medium Priority

1. Viral metagenomic sequencing: Apply unbiased metagenomic sequencing to PLEVA lesional tissue to identify potential viral triggers that may have been missed by targeted PCR-based studies.

2. Prospective MF progression cohort: Follow patients with atypical PL (loss of CD2/CD5/CD7, T-cell clonality) prospectively with standardized surveillance (annual skin biopsies, TCR clonality monitoring) to better quantify and predict MF progression risk.

3. FUMHD biomarker discovery: Prospective collection of blood samples from FUMHD patients at presentation and during treatment to identify prognostic biomarkers beyond the clinical risk score.

Lower Priority

1. Animal model development: Develop a murine model using adoptive transfer of activated CD8+ T-cells with specificity for keratinocyte antigens to recapitulate the interface dermatitis pattern.

2. Patient-reported outcomes study: Conduct a quality-of-life assessment using validated instruments (DLQI, Children's DLQI, EQ-5D) across the PL spectrum to quantify disease burden and inform health economic analyses.

3. Pharmacogenomic profiling: For patients on methotrexate or other systemic agents, investigate whether common pharmacogenomic variants (MTHFR, ABCB1) predict treatment response or toxicity in the PLEVA context.

Ontology Term Summary

MONDO

• MONDO:0024250 — Pityriasis lichenoides et varioliformis acuta

HPO Terms

• HP:0200034 — Papule
• HP:0200037 — Vesiculobullous skin lesion
• HP:0200042 — Skin ulcer
• HP:0040189 — Scaling skin
• HP:0000989 — Pruritus
• HP:0001945 — Fever
• HP:0007513 — Generalized hypopigmentation of skin
• HP:0100699 — Scarring
• HP:0001047 — Crusting erythematous dermatitis
• HP:0025155 — Disseminated intravascular coagulation

GO Terms (Biological Process)

• GO:0006955 — Immune response
• GO:0002456 — T cell mediated immunity
• GO:0006915 — Apoptotic process
• GO:0006954 — Inflammatory response
• GO:0042110 — T cell activation
• GO:0006968 — Cellular defense response

CL Terms (Cell Types)

• CL:0000794 — CD8-positive, alpha-beta cytotoxic T cell
• CL:0000312 — Keratinocyte
• CL:0000115 — Endothelial cell
• CL:0000453 — Langerhans cell

UBERON Terms (Anatomy)

• UBERON:0002097 — Skin of body
• UBERON:0001003 — Skin epidermis
• UBERON:0002067 — Dermis
• UBERON:0002100 — Trunk
• UBERON:0001456 — Face

MAXO Terms (Treatment)

• MAXO:0000747 — Antimicrobial therapy
• MAXO:0000571 — Topical corticosteroid therapy
• MAXO:0000596 — Phototherapy
• MAXO:0001024 — Immunosuppressive therapy

CHEBI Terms

• CHEBI:48923 — Erythromycin
• CHEBI:2955 — Azithromycin
• CHEBI:44185 — Methotrexate
• CHEBI:4031 — Cyclosporine
• CHEBI:41879 — Dexamethasone
• CHEBI:4911 — Etoposide

Report generated: 2026-05-05 Based on systematic review of 52 peer-reviewed publications 6 confirmed findings with statistical evidence and verified citations